 Jonathan Kaufman
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 7 | 2020 | 284 | 1.580 |
Why?
| | Cardiac Surgical Procedures | 11 | 2020 | 609 | 1.560 |
Why?
| | Heart Defects, Congenital | 11 | 2020 | 913 | 1.300 |
Why?
| | Multiple Myeloma | 8 | 2024 | 291 | 1.090 |
Why?
| | Hyponatremia | 2 | 2016 | 43 | 0.870 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 1953 | 0.820 |
Why?
| | Quality Improvement | 3 | 2018 | 1285 | 0.810 |
Why?
| | Postoperative Complications | 9 | 2020 | 2916 | 0.800 |
Why?
| | Enteral Nutrition | 7 | 2020 | 216 | 0.690 |
Why?
| | Airway Extubation | 1 | 2020 | 60 | 0.590 |
Why?
| | Infant, Newborn | 23 | 2020 | 6424 | 0.570 |
Why?
| | Intensive Care Units | 5 | 2020 | 916 | 0.560 |
Why?
| | Cardiac Care Facilities | 1 | 2017 | 11 | 0.540 |
Why?
| | Vascular Access Devices | 1 | 2018 | 30 | 0.540 |
Why?
| | Dexamethasone | 9 | 2024 | 370 | 0.530 |
Why?
| | Postoperative Care | 3 | 2014 | 288 | 0.510 |
Why?
| | Heart Diseases | 3 | 2016 | 349 | 0.510 |
Why?
| | Hypernatremia | 1 | 2016 | 8 | 0.500 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2014 | 120 | 0.470 |
Why?
| | Vasodilator Agents | 3 | 2013 | 331 | 0.460 |
Why?
| | Stem Cell Transplantation | 2 | 2022 | 191 | 0.460 |
Why?
| | Boronic Acids | 3 | 2014 | 37 | 0.430 |
Why?
| | Tachycardia | 2 | 2014 | 57 | 0.430 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 53 | 0.420 |
Why?
| | Infant | 18 | 2020 | 10022 | 0.410 |
Why?
| | Blood Chemical Analysis | 1 | 2014 | 108 | 0.410 |
Why?
| | Pyrazines | 3 | 2014 | 92 | 0.410 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 105 | 0.410 |
Why?
| | Infant, Premature | 3 | 2020 | 611 | 0.400 |
Why?
| | Milrinone | 1 | 2013 | 26 | 0.400 |
Why?
| | Norwood Procedures | 1 | 2013 | 29 | 0.400 |
Why?
| | Calcitonin | 1 | 2013 | 27 | 0.400 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.400 |
Why?
| | Prilocaine | 1 | 2013 | 5 | 0.390 |
Why?
| | Methemoglobinemia | 1 | 2013 | 13 | 0.390 |
Why?
| | Lidocaine | 1 | 2013 | 54 | 0.380 |
Why?
| | Protein Precursors | 1 | 2013 | 136 | 0.370 |
Why?
| | Antibodies, Monoclonal | 5 | 2025 | 1519 | 0.370 |
Why?
| | Tidal Volume | 1 | 2013 | 111 | 0.370 |
Why?
| | Bronchiolitis | 1 | 2013 | 87 | 0.370 |
Why?
| | Masks | 1 | 2013 | 70 | 0.370 |
Why?
| | Nutritional Status | 1 | 2015 | 354 | 0.360 |
Why?
| | Anesthetics, Local | 1 | 2013 | 100 | 0.360 |
Why?
| | Thrombosis | 2 | 2018 | 393 | 0.360 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2013 | 88 | 0.360 |
Why?
| | Cardiac Output, Low | 1 | 2012 | 54 | 0.360 |
Why?
| | Critical Illness | 2 | 2016 | 889 | 0.360 |
Why?
| | Cardiotonic Agents | 1 | 2012 | 95 | 0.350 |
Why?
| | Catheter Obstruction | 1 | 2011 | 4 | 0.340 |
Why?
| | Weight Gain | 1 | 2015 | 556 | 0.330 |
Why?
| | C-Reactive Protein | 1 | 2013 | 416 | 0.330 |
Why?
| | Chylothorax | 1 | 2010 | 20 | 0.330 |
Why?
| | Octreotide | 1 | 2010 | 23 | 0.330 |
Why?
| | Length of Stay | 6 | 2018 | 1335 | 0.320 |
Why?
| | Heart Rate | 1 | 2013 | 849 | 0.300 |
Why?
| | Heparin | 1 | 2011 | 243 | 0.300 |
Why?
| | Bortezomib | 7 | 2024 | 55 | 0.300 |
Why?
| | Abnormalities, Multiple | 1 | 2011 | 197 | 0.300 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 94 | 0.300 |
Why?
| | Catheterization, Central Venous | 1 | 2011 | 122 | 0.290 |
Why?
| | Seizures | 1 | 2013 | 460 | 0.290 |
Why?
| | Retrospective Studies | 17 | 2020 | 17009 | 0.290 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 5 | 2013 | 97 | 0.290 |
Why?
| | Gastrostomy | 2 | 2020 | 130 | 0.290 |
Why?
| | Humans | 49 | 2025 | 144261 | 0.280 |
Why?
| | Vasculitis | 1 | 2008 | 68 | 0.280 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2012 | 382 | 0.270 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2015 | 124 | 0.270 |
Why?
| | Male | 36 | 2025 | 72035 | 0.270 |
Why?
| | Sepsis | 1 | 2013 | 640 | 0.250 |
Why?
| | Palliative Care | 1 | 2015 | 996 | 0.240 |
Why?
| | Colorado | 5 | 2020 | 4562 | 0.240 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2025 | 985 | 0.240 |
Why?
| | Female | 34 | 2025 | 77976 | 0.240 |
Why?
| | Receptor, ErbB-3 | 1 | 2025 | 48 | 0.230 |
Why?
| | Neuregulin-1 | 1 | 2025 | 49 | 0.230 |
Why?
| | Critical Care | 1 | 2011 | 694 | 0.220 |
Why?
| | Respiration, Artificial | 3 | 2020 | 707 | 0.220 |
Why?
| | Prospective Studies | 8 | 2025 | 7970 | 0.210 |
Why?
| | Incidence | 5 | 2020 | 2870 | 0.210 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2018 | 41 | 0.200 |
Why?
| | Rhabdomyosarcoma | 1 | 2024 | 64 | 0.200 |
Why?
| | Biomarkers | 3 | 2016 | 4254 | 0.200 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5389 | 0.190 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 320 | 0.190 |
Why?
| | Intubation, Gastrointestinal | 2 | 2020 | 82 | 0.190 |
Why?
| | Child, Preschool | 12 | 2019 | 11774 | 0.190 |
Why?
| | Maintenance Chemotherapy | 1 | 2022 | 42 | 0.180 |
Why?
| | Child | 12 | 2024 | 22537 | 0.180 |
Why?
| | Cohort Studies | 5 | 2019 | 5935 | 0.180 |
Why?
| | Acute Kidney Injury | 4 | 2020 | 862 | 0.180 |
Why?
| | Time Factors | 8 | 2017 | 7155 | 0.180 |
Why?
| | Disease-Free Survival | 5 | 2022 | 768 | 0.180 |
Why?
| | Cyclophosphamide | 5 | 2020 | 266 | 0.180 |
Why?
| | Rituximab | 6 | 2015 | 209 | 0.170 |
Why?
| | Drug Administration Schedule | 6 | 2014 | 778 | 0.170 |
Why?
| | Cyanosis | 1 | 2020 | 17 | 0.160 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 8 | 0.160 |
Why?
| | Risk Factors | 8 | 2020 | 10699 | 0.160 |
Why?
| | Analysis of Variance | 2 | 2013 | 1304 | 0.160 |
Why?
| | Fundoplication | 1 | 2020 | 54 | 0.160 |
Why?
| | Smoldering Multiple Myeloma | 1 | 2019 | 7 | 0.160 |
Why?
| | Calcaneus | 1 | 2019 | 31 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 1050 | 0.150 |
Why?
| | Lymphoma, B-Cell | 2 | 2012 | 132 | 0.140 |
Why?
| | Ketorolac | 1 | 2018 | 30 | 0.140 |
Why?
| | Treatment Outcome | 10 | 2020 | 11643 | 0.140 |
Why?
| | Platelet Aggregation | 1 | 2018 | 103 | 0.140 |
Why?
| | Gastroesophageal Reflux | 1 | 2020 | 236 | 0.130 |
Why?
| | Urine Specimen Collection | 1 | 2017 | 2 | 0.130 |
Why?
| | Catheters, Indwelling | 1 | 2018 | 96 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1264 | 0.130 |
Why?
| | Morphine | 1 | 2018 | 168 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 2026 | 0.120 |
Why?
| | Diuretics | 1 | 2016 | 68 | 0.120 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 69 | 0.120 |
Why?
| | Sodium | 1 | 2016 | 197 | 0.120 |
Why?
| | Lymphoma, Follicular | 2 | 2015 | 56 | 0.110 |
Why?
| | Bone Density | 1 | 2019 | 482 | 0.110 |
Why?
| | Aged | 12 | 2025 | 25850 | 0.110 |
Why?
| | Logistic Models | 4 | 2014 | 2104 | 0.110 |
Why?
| | Prognosis | 5 | 2018 | 4278 | 0.110 |
Why?
| | Urinary Tract Infections | 1 | 2017 | 202 | 0.110 |
Why?
| | Thalidomide | 2 | 2015 | 43 | 0.110 |
Why?
| | Gestational Age | 2 | 2020 | 975 | 0.110 |
Why?
| | Transplantation, Autologous | 3 | 2022 | 290 | 0.100 |
Why?
| | Quality of Life | 2 | 2024 | 3166 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2005 | 1980 | 0.100 |
Why?
| | Heart | 1 | 2018 | 633 | 0.100 |
Why?
| | Remission Induction | 2 | 2014 | 306 | 0.100 |
Why?
| | Port-Wine Stain | 1 | 2013 | 3 | 0.100 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 40 | 0.100 |
Why?
| | Liver Function Tests | 1 | 2013 | 106 | 0.100 |
Why?
| | Delivery Rooms | 1 | 2013 | 9 | 0.100 |
Why?
| | Adult | 13 | 2025 | 40262 | 0.100 |
Why?
| | Pediatrics | 2 | 2011 | 1112 | 0.090 |
Why?
| | Administration, Topical | 1 | 2013 | 150 | 0.090 |
Why?
| | Middle Aged | 12 | 2025 | 35762 | 0.090 |
Why?
| | Equipment Failure | 1 | 2013 | 115 | 0.090 |
Why?
| | Health Care Surveys | 2 | 2011 | 538 | 0.090 |
Why?
| | Intubation | 1 | 2012 | 7 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 427 | 0.090 |
Why?
| | Lung | 1 | 2005 | 4108 | 0.090 |
Why?
| | Respiration | 1 | 2013 | 206 | 0.090 |
Why?
| | Pentobarbital | 1 | 2011 | 17 | 0.090 |
Why?
| | Australia | 1 | 2013 | 286 | 0.090 |
Why?
| | Survival Rate | 2 | 2013 | 2088 | 0.090 |
Why?
| | Vein of Galen Malformations | 1 | 2011 | 2 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 218 | 0.090 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2011 | 27 | 0.080 |
Why?
| | Heterocyclic Compounds | 1 | 2011 | 23 | 0.080 |
Why?
| | Status Epilepticus | 1 | 2011 | 56 | 0.080 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 35 | 0.080 |
Why?
| | Professional Practice | 1 | 2011 | 57 | 0.080 |
Why?
| | Airway Obstruction | 1 | 2013 | 162 | 0.080 |
Why?
| | Down Syndrome | 1 | 2018 | 534 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 546 | 0.080 |
Why?
| | Linear Models | 1 | 2013 | 850 | 0.080 |
Why?
| | Receptors, CXCR4 | 1 | 2011 | 91 | 0.080 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2011 | 53 | 0.080 |
Why?
| | Chemoprevention | 1 | 2011 | 90 | 0.080 |
Why?
| | Nutritional Support | 1 | 2010 | 39 | 0.080 |
Why?
| | Diet, Fat-Restricted | 1 | 2010 | 79 | 0.080 |
Why?
| | Ventilator Weaning | 1 | 2010 | 39 | 0.080 |
Why?
| | Anesthetics, Intravenous | 1 | 2010 | 69 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2011 | 307 | 0.080 |
Why?
| | Aortic Coarctation | 1 | 2011 | 79 | 0.080 |
Why?
| | Electrocardiography | 1 | 2013 | 660 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2870 | 0.080 |
Why?
| | ROC Curve | 1 | 2012 | 612 | 0.080 |
Why?
| | Salvage Therapy | 1 | 2011 | 162 | 0.080 |
Why?
| | Propofol | 1 | 2010 | 85 | 0.080 |
Why?
| | Infusions, Intravenous | 3 | 2018 | 423 | 0.080 |
Why?
| | Kinetics | 1 | 2013 | 1627 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 431 | 0.080 |
Why?
| | Birth Weight | 1 | 2013 | 522 | 0.080 |
Why?
| | Drainage | 1 | 2010 | 185 | 0.080 |
Why?
| | Maximum Tolerated Dose | 3 | 2015 | 212 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 214 | 0.080 |
Why?
| | Lymphoma | 1 | 2011 | 232 | 0.070 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 1131 | 0.070 |
Why?
| | Device Removal | 1 | 2010 | 142 | 0.070 |
Why?
| | Plasmapheresis | 1 | 2008 | 22 | 0.070 |
Why?
| | Alprostadil | 1 | 2008 | 29 | 0.070 |
Why?
| | High-Frequency Ventilation | 1 | 2008 | 45 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1487 | 0.070 |
Why?
| | Vincristine | 3 | 2015 | 140 | 0.070 |
Why?
| | Renal Replacement Therapy | 1 | 2008 | 99 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1495 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 1137 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 964 | 0.060 |
Why?
| | Neoadjuvant Therapy | 1 | 2010 | 462 | 0.060 |
Why?
| | Adolescent | 8 | 2018 | 22281 | 0.060 |
Why?
| | Doxorubicin | 3 | 2015 | 397 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2111 | 0.060 |
Why?
| | Patient Readmission | 1 | 2012 | 756 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2008 | 255 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2010 | 780 | 0.060 |
Why?
| | Interferons | 1 | 2007 | 188 | 0.060 |
Why?
| | Preoperative Care | 1 | 2008 | 379 | 0.060 |
Why?
| | Anticoagulants | 1 | 2011 | 721 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 478 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8243 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2005 | 83 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 3079 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 846 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2022 | 2192 | 0.050 |
Why?
| | Hemorrhage | 1 | 2008 | 809 | 0.050 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 1182 | 0.050 |
Why?
| | Prednisone | 2 | 2015 | 221 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 459 | 0.050 |
Why?
| | Autografts | 1 | 2022 | 55 | 0.050 |
Why?
| | Melphalan | 1 | 2022 | 42 | 0.050 |
Why?
| | Boron Compounds | 1 | 2022 | 29 | 0.050 |
Why?
| | Thrombocytopenia | 2 | 2015 | 205 | 0.050 |
Why?
| | Pneumonia | 2 | 2020 | 630 | 0.040 |
Why?
| | Lung Diseases | 1 | 2008 | 787 | 0.040 |
Why?
| | Glycine | 1 | 2022 | 187 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3592 | 0.040 |
Why?
| | Recurrence | 2 | 2015 | 1134 | 0.040 |
Why?
| | Viscera | 1 | 2020 | 17 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2917 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 2020 | 51 | 0.040 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2020 | 85 | 0.040 |
Why?
| | Cellulitis | 1 | 2020 | 53 | 0.040 |
Why?
| | Nervous System | 1 | 2020 | 70 | 0.040 |
Why?
| | South Africa | 1 | 2019 | 221 | 0.040 |
Why?
| | Heart Failure | 1 | 2012 | 2314 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 1 | 2020 | 221 | 0.030 |
Why?
| | Postoperative Period | 1 | 2018 | 353 | 0.030 |
Why?
| | Thrombelastography | 1 | 2018 | 178 | 0.030 |
Why?
| | Anti-Retroviral Agents | 1 | 2019 | 240 | 0.030 |
Why?
| | Infant Mortality | 1 | 2018 | 123 | 0.030 |
Why?
| | Rats | 1 | 2005 | 5592 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 338 | 0.030 |
Why?
| | Specimen Handling | 1 | 2017 | 185 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1646 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 768 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2840 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2015 | 133 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2014 | 94 | 0.030 |
Why?
| | Oligopeptides | 1 | 2015 | 268 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 216 | 0.020 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 11 | 0.020 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 243 | 0.020 |
Why?
| | Liver Failure | 1 | 2013 | 83 | 0.020 |
Why?
| | Neutropenia | 1 | 2013 | 155 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2011 | 28 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 847 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2926 | 0.020 |
Why?
| | Neural Conduction | 1 | 2012 | 92 | 0.020 |
Why?
| | Cytarabine | 1 | 2011 | 66 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2012 | 124 | 0.020 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 297 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2011 | 130 | 0.020 |
Why?
| | Benzylamines | 1 | 2011 | 42 | 0.020 |
Why?
| | Prostaglandins | 1 | 2011 | 94 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1382 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.020 |
Why?
| | Mouth | 1 | 2011 | 88 | 0.020 |
Why?
| | Blood Component Removal | 1 | 2011 | 28 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2011 | 89 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3637 | 0.020 |
Why?
| | Internationality | 1 | 2011 | 156 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2013 | 288 | 0.020 |
Why?
| | Indoles | 1 | 2014 | 501 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 2025 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 532 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 623 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 420 | 0.020 |
Why?
| | Animals | 2 | 2010 | 38030 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2012 | 1027 | 0.020 |
Why?
| | Internet | 1 | 2011 | 698 | 0.020 |
Why?
| | Young Adult | 2 | 2011 | 13990 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1884 | 0.010 |
Why?
| | Immunotherapy | 1 | 2007 | 652 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1705 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5988 | 0.010 |
Why?
| | United States | 1 | 2011 | 15876 | 0.010 |
Why?
| | Mice | 1 | 2010 | 18329 | 0.010 |
Why?
|
|
Kaufman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|